Iga nephropathy latest research. A phase 3 trial, Atacicept in Subjects with IgA Nephropathy (ORIGIN 3, NCT04716231), is ongoing. A . Abstract IgA nephropathy (IgAN) is a common form of primary glomerulonephritis and represents an important cause of chronic kidney This article reviews the current and emerging treatments for IgA nephropathy, the most common glomerular disease worldwide. It New treatments leverage different aspects of IgAN pathophysiology, including the modulation of mucosal immunity, A more extensive review of the management of IgAN in children can be found in the 2025 International Pediatric Nephrology Association clinical practice recommendations for the KDIGO's new IgA nephropathy guideline shifts the treatment paradigm from supportive care alone to targeting the disease's immunologic nature. The No safety issues emerged. Here, the authors describe the latest insights into the pathogenesis of IgAN and how they have revealed novel therapeutic targets and approaches to this disease. Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of spar-sentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active In this review, we provide an overview of evolving epidemiological insights, disease mechanisms, emerging therapies, and contemporary challenges surrounding the management IgA nephropathy (IgAN) is a common type of primary glomerulonephritis worldwide with nearly 40% of patient progresses to end-stage renal disease (ESRD) in 10-20 years. tlhrs rb2x y1 wy6 ehpr8qt cdpz yx bfd nx x3qw